医薬品サプライチェーン管理におけるブロックチェーンの世界市場-2025～2033年

世界の医薬品サプライチェーン管理におけるブロックチェーン市場は、2024年に12億7,000万米ドルに達し、2033年には65億7,000万米ドルに達すると予測され、予測期間2025～2033年のCAGRは21.5%で成長すると予測されています。

ブロックチェーンは、多数のコンピュータ間の取引を安全に記録する分散型の分散台帳技術です。医薬品サプライチェーンでは、製造から流通、エンドユーザーまで、医薬品に関わるあらゆる取引の不変かつ透明性のある記録を維持します。このシステムにより、すべての利害関係者、製造業者、流通業者、薬局、規制当局が、医薬品の状態や有効性に関するデータにリアルタイムでアクセスできるようになります。ブロックチェーンの暗号化された性質は、機密データを不正アクセスや不正操作から保護します。ブロックチェーンは、スマートコントラクトによって活動を自動化することで、業務を合理化し、管理コストを最小限に抑え、サプライチェーンのタイムラインを強化することができます。

データの安全性、透明性、トレーサビリティの向上は、予測期間中の市場を牽引する要因です。偽造医薬品の増加という重大な懸念に対処するため、医薬品のトレーサビリティサービスが開始されています。例えば、2024年11月、エチオピア食品医薬品局（EFDA）とMedical Value Chainは、最先端のブロックチェーン対応医薬品追跡システムを導入するための戦略的パートナーシップを発表しました。これは偽造医薬品に対抗し、安全性、真正性を確保するのに役立ちます。

市場力学：

促進要因と阻害要因

セキュリティ、透明性、トレーサビリティの向上

データセキュリティ、透明性、トレーサビリティの向上は、医薬品サプライチェーン管理市場におけるブロックチェーンの世界の成長の重要な要因になると予想されます。製薬業界が偽造医薬品、データ漏洩、規制遵守などの課題に直面する中、ブロックチェーンはこれらの重大な懸念に効果的に対処する画期的なアプローチとして浮上しています。

データセキュリティの向上は、ブロックチェーン技術の最も魅力的な利点の一つです。ブロックチェーンは非中央集権的で不変の台帳を使用し、すべての取引記録が安全に保存され、正当な権限なしに編集や破棄ができないようにします。この機能により、旧来の中央集権型システムにありがちなデータ漏えいや不正操作の可能性が徐々に低下しています。昨今、多くのデータ漏えいが発生しています。例えば、2023年には540以上の組織と1億1,200万人以上の個人がHHS市民権局（OCR）に報告されたヘルスケアデータ侵害に関与しており、2022年には590の組織と4,860万人が影響を受けました。2022年に報告された100万件以上の医療データ漏えいは11件、さらに50万件以上のデータ漏えいは14件ありました。ブロックチェーン技術はデータセキュリティにおいて極めて重要な役割を果たしています。

世界中で偽造医薬品が増加していることが促進要因の1つであり、偽造医薬品の生産を克服するために医薬品トレーサビリティサービスが必要とされています。例えば、Pfizerが発表した記事によると、少なくとも104種類のPfizerの医薬品の偽造品が116カ国以上で確認されています。ファーマシューティカル・セキュリティ・インスティテュート（PSI）によると、2023年には142カ国で6,897件の医薬品の偽造、違法転用、窃盗事件が警察当局によって摘発されました。この犯罪には、あらゆる治療カテゴリーにわたる2,440種類以上の医薬品が関与していました。2023年にPSIが記録した医薬品犯罪の検挙件数は4,894件で、22年連続で最多を記録しました。そのため、データ侵害の増加や偽造医薬品の製造は、医薬品サプライチェーン管理市場におけるブロックチェーンの需要を高めています。

高い初期投資

高額な初期投資などの要因が、世界の医薬品サプライチェーン管理におけるブロックチェーン市場を阻害すると予想されています。ブロックチェーンソリューションの開発には、技術インフラ、ソフトウェア開発、従業員トレーニングへの投資など、多額の先行投資が発生します。組織は、ブロックチェーンの運用を可能にする適切なテクノロジーとソフトウェアを購入しなければならず、これは大きなコストとなり得ます。さらに、こうしたシステムの構築や管理には専門的なスキルが必要なため、価格も上昇します。多くの企業は、特に投資収益率（ROI）がすぐに明らかでない場合、これらの費用を正当化するのに苦労するかもしれません。このような躊躇は、医薬品サプライチェーンにおけるブロックチェーン技術の全体的な採用を妨げる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • データセキュリティ、透明性、トレーサビリティの向上
  • 抑制要因
  • 初期投資額が高い
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 提供物別

• プラットフォーム
• サービス

第7章 用途別

• 医薬品のトレーサビリティ
• 在庫管理
• スマートコントラクト
• コンプライアンス管理
• 支払いと決済
• その他

第8章 タイプ別

• プライベートブロックチェーン
• パブリックブロックチェーン
• ハイブリッドブロックチェーン

第9章 エンドユーザー別

• メーカー
• 販売代理店
• ヘルスケア提供者

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• IBM
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Microsoft
• SAP SE
• Oracle
• Cloud Software Group, Inc.
• Auxesis Infotech Pvt. Ltd.
• Omnichain Solutions
• Walmart Inc.
• FarmaTrust
• Amazon Web Services, Inc.

第13章 付録

The global blockchain in pharmaceutical supply chain management market reached US$ 1.27 billion in 2024 and is expected to reach US$ 6.57 billion by 2033, growing at a CAGR of 21.5% during the forecast period 2025-2033.

Blockchain is a decentralized, distributed ledger technology that securely records transactions between numerous computers. In the context of pharmaceutical supply chains, it maintains an immutable and transparent record of every transaction involving pharmaceutical products, from production to distribution to end users. This system allows all stakeholders, manufacturers, distributors, pharmacies, and regulators to access real-time data about the status and validity of pharmaceuticals. The cryptographic nature of blockchain safeguards sensitive data from unauthorized access and manipulation. Blockchain, by automating activities via smart contracts, can streamline operations, minimize administrative costs, and enhance supply chain timelines.

The improved data security, transparency, and traceability is the driving factor that drives the market over the forecast period. To address critical concerns about increasing the number of counterfeit pharmaceuticals, drug traceability services are launched. For instance, in November 2024, the Ethiopia Food and Drug Authority (EFDA), and Medical Value Chain announced strategic partnerships to implement cutting-edge blockchain-enabled pharmaceutical track and track system. This helps in combating counterfeit medicines and ensuring safety, authenticity.

Market Dynamics: Drivers & Restraints

Improved security, transparency, and traceability

Improved data security, transparency, and traceability is expected to be a significant factor in the growth of the global blockchain in the pharmaceutical supply chain management market. As the pharmaceutical industry faces challenges such as counterfeit pharmaceuticals, data breaches, and regulatory compliance, blockchain emerges as a revolutionary approach that effectively addresses these critical concerns.

Improved data security is one of the most appealing benefits of blockchain technology. Blockchain uses a decentralized and immutable ledger to ensure that all transaction records are securely stored and cannot be edited or destroyed without valid authority. This feature gradually decreases the likelihood of data breaches and manipulation, which are common in older centralized systems. In recent times, there have been many data breaches. For instance, in 2023, more than 540 organizations and 112 million individuals were implicated in healthcare data breaches reported to the HHS Office for Civil Rights (OCR), compared to 590 organizations and 48.6 million impacted individuals in 2022. There were 11 reported healthcare data breaches of more than 1 million records in 2022 and a further 14 data breaches of over 500,000 records. Blockchain technology plays a crucial role in data security.

The increasing number of counterfeit pharmaceuticals across the globe is one of the driving factors and it needs drug traceability services to overcome the production of counterfeit pharmaceuticals. For instance, according to an article published by Pfizer, counterfeit versions of at least 104 Pfizer medicines have been confirmed in more than 116 countries. According to the Pharmaceutical Security Institute (PSI), law enforcement officials uncovered 6,897 incidents of counterfeiting, illegal diversion, and theft of pharmaceuticals in 142 countries in 2023. The crimes involved more than 2,440 different medicines across every therapeutic category. The PSI documented 4,894 arrests for pharmaceutical crime in 2023, the largest number of arrests achieved in 22 consecutive years of data. So, the increasing number of data breaches and the production of counterfeit pharmaceuticals increase the demand for the blockchain in the pharmaceutical supply chain management market.

High initial investment

Factors such as high initial investment are expected to hamper the global blockchain in pharmaceutical supply chain management market. Implementing blockchain solutions incurs significant upfront expenditures, including investments in technical infrastructure, software development, and employee training. Organizations must purchase the appropriate technology and software to enable blockchain operations, which can be a major cost. Furthermore, the necessity for specialized skills to build and administer these systems drives up prices. Many businesses may struggle to justify these charges, particularly when the return on investment (ROI) is not immediately obvious. This hesitation may hinder the overall adoption of blockchain technology in the pharmaceutical supply chain.

Segment Analysis

The global blockchain in the pharmaceutical supply chain management market is segmented based on offerings, application, type, end-user, and region.

Drug traceability segment is expected to dominate the global blockchain in pharmaceutical supply chain management market share

The drug traceability segment is the most dominant due to its critical role in enhancing safety, compliance, and operational efficiency within the pharmaceutical industry. As the threat of counterfeit drugs grows, stakeholders recognize the importance of strong traceability systems that can ensure the authenticity and integrity of pharmaceutical products throughout their lifecycle. Drug traceability is the process of tracking pharmaceuticals from their point of manufacture to the final consumer. This procedure is critical for preventing counterfeit pharmaceuticals from entering the supply chain, which poses serious threats to patient safety and public health. Blockchain technology provides a decentralized, immutable database that records all drug-related transactions, creating a transparent and traceable history. This feature not only aids in the detection and elimination of counterfeit products but also assures compliance with regulatory standards requiring strict pharmaceutical tracking.

The number of counterfeit pharmaceuticals is increasing day by day. The increase in the number of counterfeit pharmaceuticals increases the demand for drug traceability services. For instance, according to the World Health Organization, at least 1 in 10 medicines in low- and middle-income countries are substandard or falsified. Countries spend an estimated US$ 30.5 billion per year on substandard and falsified medical products. Substandard and falsified medical products are often sold online or in informal markets. Moreover, according to the National Institute of Health, it has been estimated that up to 15% of all sold drugs are fake, and in parts of Africa and Asia this figure exceeds 50%. The FDA estimates that fake drugs comprise approximately 10% of the global medicine market. The number of investigations of possible counterfeit drugs by the FDA has jumped from about five per year in the 1990s to more than 20 per year since 2000.

There are recent launches of blockchain-based drug traceability services. For instance, in May 2024, Merck, a leading scientific and technological firm, introduced the M-Trace Software & Mobile App, a comprehensive data tracking solution for digitizing sterility testing. The software improves overall process safety by automatically documenting data at each stage of the testing process. This decreases the chances of divergence, false positive results, and human error. The increasing number of counterfeit pharmaceuticals and recent launches of blockchain-based drug traceability services drive the market of this segment making the drug traceability segment a dominant one.

Geographical Analysis

North America is expected to hold a significant position in the global blockchain in pharmaceutical supply chain management market share

The blockchain in the pharmaceutical supply chain management market in the North American Region is driven by several key factors that underscore its robust industrial landscape and consumer demand, increasing number of cybercrimes, strong regulatory support, and increasing awareness of the benefits of blockchain technology and increased number of launches.

In recent times, there have been launches of blockchain services in this region. For instance, in May 2023, Patientory Inc., the creator of a blockchain-based, HIPAA-compliant, private medical data ecosystem, announced today that it has launched two solutions, Patientory Consumer Decentralized Application-designed to help patients more efficiently and securely store and earn money from their medical data and Neith Enterprise Dashboard in partnership with Prosper Healthtech, a community-backed organization committed to equity in Birmingham offering a supportive network of organizations throughout the city, including UAB Hospital, PackHealth, and Blue Cross Blue Shield.

The increasing number of cybercrimes is one of the major drivers in this region. The cybercrimes can be reduced by storing the systems securely using software blockchain services. For instance, according to an article posted by Palo Alto Networks in January 2024, Malicious attacks on healthcare have grown exponentially in recent years. According to the HHS Office for Civil Rights (OCR), large breaches increased by 93% between 2018 and 2023. Additionally, large breaches involving ransomware increased by 278%.

The increase in the number of counterfeit pharmaceuticals in this region increases the demand for global blockchain in pharmaceutical supply chain management which helps in the marketing of original products. For instance, in January 2024, the FDA alerted healthcare professionals and consumers that unsafe counterfeit versions of Botox (botulinum toxin) have been found in multiple states and administered to consumers for cosmetic purposes. Moreover, in December 2023, the FDA investigated and announced that a counterfeit Ozempic (semaglutide) injection of 1 milligram (mg) was found and the U.S. drug supply chain seized thousands of units of the product. All these factors make North America hold the highest market share.

Asia Pacific is growing at the fastest pace in the global blockchain in pharmaceutical supply chain management market

Asia Pacific's rapid growth in the Global Blockchain in Pharmaceutical Supply Chain Management Market is driven by a combination of factors including the booming e-commerce sector, increasing industrialization, proactive technology adoption, increasing number of counterfeit versions, and supportive government initiatives. The Asia Pacific area is rapidly industrializing, resulting in rising consumer markets that require improved supply chain visibility and efficiency. Countries like as China, India, and Japan are at the forefront of using blockchain technology to simplify processes and combat counterfeit products.

The rapid expansion of the e-commerce sector is a major driver of blockchain implementation in the Asia Pacific pharmaceutical supply chain. As e-commerce grows more popular, there is a greater demand for efficient and transparent supply chain solutions that guarantee timely delivery and product authenticity. Blockchain technology provides a reliable foundation for tracking pharmaceuticals along the supply chain, giving stakeholders real-time visibility into product movements.

Competitive Landscape

The major global players in the global blockchain in pharmaceutical supply chain management market include IBM, Microsoft, SAP SE, Oracle, Cloud Software Group, Inc., Auxesis Infotech Pvt. Ltd., Omnichain Solutions, Walmart Inc., FarmaTrust, Amazon Web Services, Inc. among others.

Emerging Players

VeChain, Modum, and Everledger among others

Key Developments

• In September 2023, the Republic of Mauritius launched a blockchain-based eVerify service. E-Verify is a system that uses blockchain to verify and authenticate information or transactions electronically. Emerging technologies such as blockchain, big data, Artificial Intelligence, and the internet create new ways for consumers to interact while disrupting traditional business models.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global blockchain in pharmaceutical supply chain management market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Offerings
• 3.2. Snippet by Application
• 3.3. Snippet by Type
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Improved Data Security, Transparency, And Traceability
  • 4.1.3. Restraints
  • 4.1.4. High Initial Investment
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Offerings

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offerings
  • 6.1.2. Market Attractiveness Index, By Offerings
• 6.2. Platform*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Service

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Drug Traceability*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Inventory Monitoring
• 7.4. Smart Contracts
• 7.5. Compliance Management
• 7.6. Payment & Settlement
• 7.7. Others

8. By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Private Blockchain*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Public Blockchain
• 8.4. Hybrid Blockchain

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Manufacturers*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Distributors
• 9.4. Healthcare Providers

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
    • 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), Offerings
    • 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. IBM*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Microsoft
• 12.3. SAP SE
• 12.4. Oracle
• 12.5. Cloud Software Group, Inc.
• 12.6. Auxesis Infotech Pvt. Ltd.
• 12.7. Omnichain Solutions
• 12.8. Walmart Inc.
• 12.9. FarmaTrust
• 12.10. Amazon Web Services, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us